Integrated Safety Analysis of Ritlecitinib for the Treatment of Alopecia Areata (AA) From the Phase 2 and Phase 3 ALLEGRO Clinical Trial Program. (2023). SKIN The Journal of Cutaneous Medicine, 7(6), s291. https://doi.org/10.25251/skin.7.supp.291